Evidence map›Paper›PMID 17606312›Full record

ArticlePeptides2007

Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.

V Lelievre, G Favrais, C Abad, H Adle-Biassette, Y Lu, P M Germano, G Cheung-Lau, J R Pisegna, P Gressens, G Lawson and 1 more

Open access · greenAbstract read
In one paragraph

Article in Peptides, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Neuroimmune Interactions in the Intestine.Annual review of immunology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

V LelievreINSERM, U676, Paris, France.
G Favrais
C Abad
H Adle-Biassette
Y Lu
P M Germano
G Cheung-Lau
J R Pisegna
P Gressens
G Lawson
J A Waschek
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · USAssistance Publique – Hôpitaux de Paris · FRDélégation Paris 7 · FRUniversité Paris Cité · FR

Funding

VIP AND PACP ACTION IN CNS DEVELOPMENT AND INJURYP01HD006576 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DE VELLIS, JEAN · 1985 to 2006
$7.8M
REGULATION OF NEURAL PRECURSORS: ROLE OF NEUROPEPTIDESR01HD034475 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASCHEK, JAMES A · 1997 to 2006
$1.6M
GENE EXPRESSION DURING IMMUNOREGULATORY CELL DEVELOPMENTK11HD000657 · NICHD · CHILDREN'S HOSPITAL OF PHILADELPHIA · PI PUCK, JENNIFER MAXWELL · 1985 to 1988
–
NICHD NIH HHS HD0657NICHD NIH HHS HD34475NICHD NIH HHS P01 HD006576NICHD NIH HHS R01 HD034475
6 · The paper itself

Abstract

In 1970, Drs. Said and Mutt isolated a novel peptide from porcine intestinal extracts with powerful vasoactive properties, and named it vasoactive intestinal peptide (VIP). Since then, the biological actions of VIP in the gut as well as its signal transduction pathways have been extensively studied. A variety of in vitro and in vivo studies have indicated that VIP, expressed in intrinsic non-adrenergic non-cholinergic (NANC) neurons, is a potent regulator of gastrointestinal (GI) motility, water absorption and ion flux, mucus secretion and immune homeostasis. These VIP actions are believed to be mediated mainly by interactions with highly expressed VPAC(1) receptors and the production of nitric oxide (NO). Furthermore, VIP has been implicated in numerous physiopathological conditions affecting the human gut, including pancreatic endocrine tumors secreting VIP (VIPomas), insulin-dependent diabetes, Hirschsprung's disease, and inflammatory bowel syndromes such as Crohn's disease and ulcerative colitis. To further understand the physiological roles of VIP on the GI tract, we have begun to analyze the anatomical and physiological phenotype of C57BL/6 mice lacking the VIP gene. Herein, we demonstrate that the overall intestinal morphology and light microscopic structure is significantly altered in VIP(-/-) mice. Macroscopically there is an overall increase in weight, and decrease in length of the bowel compared to wild type (WT) controls. Microscopically, the phenotype was characterized by thickening of smooth muscle layers, increased villi length, and higher abundance of goblet cells. Alcian blue staining indicated that the latter cells were deficient in mucus secretion in VIP(-/-) mice. The differences became more pronounced from the duodenum to the distal jejunum or ileum of the small bowel but, became much less apparent or absent in the colon with the exception of mucus secretion defects. Further examination of the small intestine revealed larger axonal trunks and unusual unstained patches in myenteric plexus. Physiologically, the VIP(-/-) mice showed an impairment in intestinal transit. Moreover, unlike WT C57BL/6 mice, a significant percentage of VIP(-/-) mice died in the first postnatal year with overt stenosis of the gut.

Indexed as

MutationAnimalsGastrointestinal MotilityGastrointestinal TractHirschsprung DiseaseIleusImmunohistochemistryMiceMice, Inbred C57BLMice, KnockoutVasoactive Intestinal PeptideVasoactive Intestinal Peptide

Identifiers

PMID17606312
PMCPMC2042583
OpenAlexW1965847743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.